Isosorbide Dinitrate And Hydralazine Hydrochloride Tablet
Product Images NDC 50742-246

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Isosorbide Dinitrate And Hydralazine Hydrochloride (NDC 50742-246). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ingenus Pharmaceuticals, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (6d0bb2ce E08c 42a3 9210 E8151fc10b57 01)

Chemical structure diagram of Isosorbide dinitrate and hydralazine hydrochloride, showing the molecular arrangement of atoms and functional groups typical for this compound in a pharmaceutical context.*

FDA Label Image

Image (6d0bb2ce E08c 42a3 9210 E8151fc10b57 02)

Chemical structure diagram of Isosorbide dinitrate and hydralazine hydrochloride active ingredients, showing molecular components including nitrogen and hydrochloride group (HCl).*

FDA Label Image

Image (6d0bb2ce E08c 42a3 9210 E8151fc10b57 03)

Kaplan-Meier plot showing time to death by all causes in Black patients comparing BiDil versus placebo. The graph displays percent survival over time in days up to 600 days. BiDil shows higher survival rates with a noted 43% reduction in mortality and statistical significance (P = 0.012, Log-Rank Test). Sample sizes for BiDil and placebo groups at various time points are provided below the graph.*

FDA Label Image

Image (6d0bb2ce E08c 42a3 9210 E8151fc10b57 04)

Kaplan-Meier plot showing time to first hospitalization for heart failure in Black patients, comparing BiDil and placebo groups over approximately 600 days. The graph displays percent without hospitalization over time, indicating a 39% risk reduction for BiDil compared to placebo. Sample sizes at various time points are included.*

FDA Label Image

Image (6d0bb2ce E08c 42a3 9210 E8151fc10b57 05)

A bar graph titled 'Change in Minnesota Living With Heart Failure Score' comparing BiDil and Placebo groups over time (3 to 18 months and endpoint). BiDil shows greater improvement with larger negative score changes than Placebo, with statistical significance indicated at multiple time points. Sample sizes for each group are noted below the timeline.*

FDA Label Image

Image (6d0bb2ce E08c 42a3 9210 E8151fc10b57 06)

A forest plot showing relative risk and 95% confidence intervals for all-cause mortality and first hospitalization for heart failure in Black patients, categorized by demographic, baseline medication, and clinical characteristic subgroups. The graph compares outcomes favoring BiDil versus placebo across groups like age, gender, heart failure etiology, hypertension, diabetes, renal insufficiency, and various medications.*

FDA Label Image

Image (6d0bb2ce E08c 42a3 9210 E8151fc10b57 07)

FDA Label Image

Bottle Label (6d0bb2ce E08c 42a3 9210 E8151fc10b57 08)

Label for Isosorbide Dinitrate and Hydralazine Hydrochloride Tablets, 20 mg/37.5 mg strength, containing 180 tablets. The product is manufactured for Ingenus Pharmaceuticals, LLC, Orlando, FL. The label includes storage instructions and a barcode, with the NDC 50742-246-18 visible. The label also indicates that the product is prescription only.*

FDA Label Image

Bottle Label 90ct (6d0bb2ce E08c 42a3 9210 E8151fc10b57 09)

Label for Isosorbide Dinitrate and Hydralazine Hydrochloride Tablets 20 mg/37.5 mg, oral dosage form by Ingenus Pharmaceuticals, LLC. The package contains 90 tablets. The label includes storage instructions, a barcode, and a note that the product is Rx only.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.